Copy
Quarterly Newsletter
   Summer 2019
Share
Tweet
Forward

Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD (ReSolve FSHD)

ReSolve FSHD has 8 actively recruiting sites in the United States and 3 actively recruiting sites in Europe.  Contact a local site today for additional information!
Recruitment Update:
Almost There!
as of July 1, 2019:

One of the most fantastic benefits of running a study is meeting all of the amazing people with FSHD from around the country and the world.  It's the participation of all of you that make a study like this so important!  Your participation in this study will not just help companies planning clinical trials now, but will help all companies wanting to develop treatments for FSHD in the future.    

-Dr. Jeffrey Statland
Our next goal is to recruit 160 US subjects by June 1, 2020. 
We have enrolled 106 so far!
I want to thank the FSHD community for their outstanding support of the ReSolve study.  We have surpassed our recruitment milestone for the past year and are on target to finish the study on time.  This is a crucial study for all future clinical trials in FSHD and because of your help, our success has attracted the attention of several companies who are considering starting drug development programs in FSHD.

-Dr. Rabi Tawil
The Patient Perspective
(A note from one of our subjects)
 
To me, it's about trying to do something meaningful. I was fortunate enough to be raised on a dairy farm.  From that, my brother and I expanded the farm operation, and continued the dairy, after high school for several years.  I really felt was doing something rewarding and useful.  With the progression of FSHD, I had to give that lifestyle up in the mid 1990's at about age 30. 

Getting involved in the Resolve Study, as well as several other Clinical Trials, has helped fill that void of trying to do something useful.  I used to think that Clinical Trials were just about testing new treatments, but that is not the case.  They need data,data,data…. Any successful research has to have the data to back it up.  That's where studies like the Resolve Study come in. I live about 120 miles from KUMC, so it wasn't always easy to make the trip, but I also feel fortunate to be close enough that I could drive.

The staff at KUMC has been great to work with. From the scheduling of the visits, to the days spent performing the different tests, it's been a very positive and rewarding experience.  I've been able to meet and work with some great people over the years just by being involved.  It would be great if my progression of FSHD could be stopped, but to me it would be very meaningful to keep someone much younger to not have to experience the same loss of muscle.    While I've been lucky to land in a rewarding job (911 Dispatcher) after leaving the farm, participating in Clinical Trials is another way to do something rewarding, and a small way to leave the world a better place.
FSHD Clinical Trial Research Network Website 

Go take a look at the new and improved FSHD CTRN website!  

http://www.kumc.edu/fshd.html
 

ReSolve Presentations at MDA Conference

Many ReSolve team members have been busy presenting around the world!  Dr. Jeff Statland presented about the Acceleron ACE-083 study and Dr. Sam LoRusso presented on the ReSolve study at the annual MDA Conference in Orlando, FL.  Dr. LoRusso had an oral presentation as well as a poster presentation. 

Kate Eichinger, the lead evaluator for the study,  presented at the MDA conference about the clinical outcome measure the FSHD COM.  Kiley Higgs and Leann Lewis also presented a poster about the FSHD Patient Advisory Council.  

ReSolve Presentations at FSH Society IRC

Lead Investigators,  Dr. Jeff Statland and Dr. Rabi Tawil recently presented at the FSH Society International Research Congress on the FSHD Clinical Trial Research Network.   

Study Criteria 


If anyone is asking about the ReSolve study, below is the criteria : 

18 month study with a total of 5 research visits
We are actively seeking FSHD1 patients at all 8 sites in the US and all 3 sites in Europe with an enrollment goal of 220 participants.

If you have any questions about these requirements, please contact one of the site coordinators below.  
Inclusion Criteria:

-FSHD1 genetically confirmed OR you have FSHD symptoms with a genetically confirmed parent, sibling or child.  

-Be able to walk 30 feet without the assistance of a person or walker. (Canes, walking sticks, or orthotic braces can be used to complete assessments safely.)

-Leg weakness (i.e. difficulty going upstairs, cannot get up from a seated position without using your hands, cannot walk long distances).
Exclusion Criteria:

-No major heart, breathing, or bone issues that would make study participation unsafe.

-Medication use should not include any muscle anabolic or catabolic agents such as steroids, oral testosterone, or oral beta agonists.

-Women who are pregnant or planning to become pregnant during the course of the study cannot participate. (Those who are postpartum or breastfeeding can safely participate.)
The Ohio State University PI, Dr. Samantha LoRusso, recently conducted a webinar with the FSH Society about FSHD.  Click the link to listen to this very informative webinar! 

https://www.youtube.com/watch?v=4fu5hH3Q5SM
 
Don't worry!  If you don't qualify for the ReSolve study, there are other options available.  Contact your local site to see what other studies may be available to you! 
ReSolve FSHD Site Contacts 
 
Kiley Higgs-University of Kansas Medical Center
Study Project Manager
Phone: 913.945.9922

Ksims2@kumc.edu
 
Leann Lewis- University of Rochester Medical Center
Lead Clinical Research Coordinator 
Phone: 585.275.7680

Leann_lewis@urmc.rochester.edu

Katie Roath- University of Kansas Medical Center
Clinical Research Coordinator 
Phone:  913.945.9928

kroath@kumc.edu
 
Mary Yep- Kennedy Krieger Institute
Clinical Research Coordinator 
Phone: 443.923.7318

Yep@kennedykrieger.org
 
Dianne DeGuzman- University of California Los Angeles
Clinical Research Coordinator 
Phone: 310.825.3264

ddeguzman@mednet.ucla.edu    
 
Marco Tellez - The Ohio State University
Clinical Research Coordinator 
Phone: 614.688.7837

Marco.Tellez@osumc.edu 
 
Laura Sissons-Ross- University of Washington
Clinical Research Coordinator 
Phone: 206.543.0081

lsissons@uw.edu
 
Sarah Moldt- University of Utah
Clinical Research Coordinator 
Phone: 801.585.9399

Sarah.moldt@hsc.utah.edu
 
Raven Pillow-Virginia Commonwealth University
Clinical Research Coordinator 
Phone: 804.404.9336

raven.pillow@vcuhealth.org 
THANK YOU FOR YOUR PARTICIPATION IN OUR STUDY!    - the ReSolve FSHD Team
Copyright © 2019 FSHD Clinical Trial Research Network, All rights reserved.


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

Email Marketing Powered by Mailchimp